Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GENETRON HOLDINGS LIMITED

(GTH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genetron : September 2021 Corporate Presentation

09/09/2021 | 11:32pm EST

CORPORATE PRESENTATION

September 2021

Disclaimer

The following presentation has been prepared by Genetron Holdings Limited ("Genetron Health" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document contains certain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1953, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Company's future financial or business performance, strategies or expectations. These statements typically contain words such as "believe," "may," "will," "could," "expects" and "anticipates" and words of similar import. Any statement in this document that is not a statement of historical fact is a forward- looking statement and involves known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. There can be no assurance that the results and events contemplated by the forward looking statements contained herein will in fact occur. None of the future projections, expectations, estimates or prospects in this document should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of assumptions, fully stated in the document. The Company also cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time and which may be beyond the Company's control. The Company assumes no duty to and does not undertake to update any forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting these statements. Factors that may materially affect our results and those risks listed in filings with the Securities and Exchange Commission.

This document also contains non-IFRS financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with International Financial Reporting Standards. In addition, the Company's calculation of these non-IFRS financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. The reconciliation of those measures to the most comparable IFRS measures is contained within this document or available at our website http://ir.genetronhealth.com.

This document speaks as of September 10, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

1

Table of Contents

1

2

3

4

5

6

7

8

Company Overview

Market Overview

Diagnosis & Monitoring

Proprietary Tech Differentiates Our Products

Biopharma Services - CDx development

Early Screening: R&D, Progress, Strategy and Commercialization

MRD New Product Line; Future Strategies and Growth Drivers

Financial Overview

2

Mission

Transform full-cycle cancer management globally by driving technological innovation and accelerating the adoption of precision medicine

Company Overview

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Genetron Holdings Ltd. published this content on 10 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 September 2021 03:31:06 UTC.


ę Publicnow 2021
All news about GENETRON HOLDINGS LIMITED
11/30Genetron Holdings Q3 Non-IFRS Loss Widens; Revenue Rises; Lowers 2021 Revenue Guidance
MT
11/30GENETRON : Health Announces Co-Development Agreement with AstraZeneca R&D China for Person..
PU
11/30Genetron Holdings Limited Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/30GENETRON : 3Q21 Presentation
PU
11/30Genetron, AstraZeneca to Collaborate to Develop Solid Tumor Tests in China
MT
11/30Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
AQ
11/30Genetron Holdings Limited Provides Revenue Guidance for the Full Year 2021
CI
11/29Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Perso..
AQ
11/16Genetron Health Reveals Two Cancer Research Study Results at the Association for Molecu..
GL
11/16Genetron Holdings Limited Reveals Two Cancer Research Study Results At the Association ..
CI
More news
Financials (USD)
Sales 2021 82,9 M - -
Net income 2021 -68,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -56,2x
Yield 2021 -
Capitalization 726 M 726 M -
Capi. / Sales 2021 8,76x
Capi. / Sales 2022 5,68x
Nbr of Employees 799
Free-Float 84,0%
Chart GENETRON HOLDINGS LIMITED
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 8,17 $
Average target price 17,51 $
Spread / Average Target 114%
EPS Revisions
Managers and Directors
Si Zhen Wang Chief Executive Officer & Director
Ce Xu Chief Financial Officer
Wei-Wu He Chairman
Hai Yan Chief Scientific Officer & Director
Yu Chen Jiao Chief Technology Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
GENETRON HOLDINGS LIMITED-41.64%726
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298